Gannon Voelbel
About Gannon Voelbel
Gannon Voelbel is the Lead of Commercial Analytics at Amylyx Pharmaceuticals, where he has worked since 2022. He has a background in analytics with previous roles at Sanofi and Putnam Associates, and he holds a Bachelor of Science in Economics and Biology from Boston College.
Current Role at Amylyx Pharmaceuticals
Gannon Voelbel serves as the Lead of Commercial Analytics at Amylyx Pharmaceuticals. He has held this position since 2022, contributing to the company's strategic decision-making processes in Cambridge, Massachusetts. His role involves analyzing commercial data to support business objectives and enhance market strategies.
Previous Experience at Sanofi
Prior to his current role, Gannon Voelbel worked at Sanofi in various analytics positions. He served as Associate Director of Analytics for a brief period in 2022. He also held the position of Senior Manager of Analytics for US Rare Blood Disorders at Sanofi Genzyme from 2021 to 2022. Additionally, he worked as Manager of Analytics for Rare Blood Disorders from 2019 to 2022, gaining extensive experience in the pharmaceutical analytics field.
Experience at Putnam Associates
Gannon Voelbel began his career at Putnam Associates, where he worked as an Associate Consultant from 2016 to 2018. He progressed to the role of Senior Associate Consultant, serving from 2018 to 2019. His time at Putnam Associates provided him with foundational skills in consulting and analytics within the healthcare sector.
Educational Background
Gannon Voelbel earned a Bachelor of Science (B.S.) in Economics and Biology from Boston College, where he studied from 2012 to 2016. His educational background equips him with a strong understanding of both economic principles and biological sciences, relevant to his work in the pharmaceutical industry.
Early Education
Before attending Boston College, Gannon Voelbel completed his high school education at Christian Brothers Academy from 2008 to 2012. This foundational education set the stage for his future academic and professional pursuits.